2nd Feb 2005 14:21
UBS AG (EMM)02 February 2005 Date of disclosure 02-Feb-2005 DISCLOSURE UNDER RULES 8.1(a), 8.1(b)(i) AND 8.3 OF THE CITY CODE ON TAKEOVERS AND MERGERS Date of dealing 01-Feb-2005 OXFORD BIOMEDICA Dealing in (1) Class of securities (e.g. ordinary ORD GBP0.01 Class of shares) securities (e.g. ordinary shares) Amount bought Amount sold Price per unit Currency (2) 500,000 0 0.2405 GBP (3) Resultant total of the same class owned or controlled (and percentage of class) 12,000,000 3.2185 % : (4) Party making disclosure UBS AG : (5) EITHER (a) Name of purchaser/vendor (Note 1) UBS AG OR (b) If dealing for discretionary client(s), name of fund management organisation (6) Reason for disclosure (Note 2) NO (a) associate of (i) offeror (Note 3) (ii) offeree company NO Specify which category or categories of associate (1- 8 overleaf) If category (8), explain (b) Rule 8.3 (i.e. disclosure because of ownership or control YES of 1% or more of the class or relevant securities dealt in) Signed, for and on behalf of the party named in (4) above:...................................................................................................................................... (Also print name of signatory) [?c=8230][?c=8230][?c=8230].E. GREGORY SMITH........ANNABEL ALLEN................................................................................. Telephone and extension number[?c=8230][?c=8230]020-7568 4981[?c=8230][?c=8230][?c=8230][?c=8230][?c=8230][?c=8230] [?c=8230][?c=8230][?c=8230][?c=8230][?c=8230].[?c=8230][?c=8230][?c=8230][?c=8230]...[?c=8230][?c=8230][?c=8230] [?c=8230] Note1. Specify owner, not nominee or vehicle company. If relevant, also identify controller of owner, e.g. where an owner normally acts on instructions of a controller. Note 2. Disclosure might be made for more than one reason; if so, state all reasons. Note 3. Specify which offeror if there is more than one. Note4. When an arrangement exists with any offeror, with the offeree company or with an associate of any offeror or of the offeree company in relation to relevant securities, details of such arrangement must be disclosed, as required Note 6 on Rule 8 For full details of disclosure requirements, see Rule 8 of the Code. If in doubt, contact the Panel on Takeovers and Mergers. Tel No: 0207-382 9026. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Oxford Biomedica